Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

ACIU AC Immune SA

2,68

-0,02 (-0,74%)

21 Dez 2024 - Geschlossen

Verzögert um 15 Minuten

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

The securities to be sold were acquired upon the vesting of previously exercised stock options on 06/01/2012 through 05/11/2016

Date of Notice

09/18/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

06/10/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Andrea M.A. Pfeifer

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

AC Immune (NASDAQ:ACIU)
Historical Stock Chart
Von Nov 2024 bis Dez 2024

Click Here for more AC Immune Charts.

AC Immune (NASDAQ:ACIU)
Historical Stock Chart
Von Dez 2023 bis Dez 2024

Click Here for more AC Immune Charts.

News AC Immune SA

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 18 Dezember 2024 (4 Tage vor) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Freitag 13 Dezember 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 10 Dezember 2024 (2 Wochen vor) • Edgar (US Regulatory)

AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
Dienstag 10 Dezember 2024 (2 Wochen vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 14 November 2024 (1 Monat vor) • Edgar (US Regulatory)

AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
Donnerstag 14 November 2024 (1 Monat vor) • GlobeNewswire Inc.

AC Immune to Present at the Jefferies 2024 London Healthcare Conference
Mittwoch 13 November 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 5 November 2024 (2 Monate vor) • Edgar (US Regulatory)

AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Dienstag 5 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Freitag 27 September 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 19 September 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 18 September 2024 (3 Monate vor) • Edgar (US Regulatory)

Weitere AC Immune SA News-Artikel

Health Care Select Sector

Euro vs Sterling

Gold vs US Dollar

Deutsche Lufthansa

Euro vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen